CJC 1295 w DAC – Premium Research Peptide

What Is CJC 1295 DAC?

CJC 1295 w DAC is a synthetic growth hormone-releasing hormone (GHRH) analog modified with a Drug Affinity Complex (DAC) that enables reversible binding to serum albumin. This modification extends the peptide’s circulating half-life from minutes to approximately 6 to 8 days, making CJC 1295 w DAC a sustained-release research tool for studying the GH/IGF-1 axis.

The core CJC 1295 w DAC structure is based on modified GRF (1-29) with four amino acid substitutions designed to resist enzymatic degradation, as detailed in the FDA’s evaluation document. These include D-Ala at position 2 to prevent DPP-IV cleavage, Gln at position 8 to avoid asparagine rearrangement, Ala at position 15, and Leu at position 27 to prevent methionine oxidation. The DAC moiety is attached via a lysine linker and consists of a maleimidopropionic acid coupled to a peptide that binds albumin.

According to the FDA’s evaluation, the albumin-binding mechanism is believed to account for the extended stability of CJC 1295 w DAC compared to unmodified GHRH(1-29), though direct comparative pharmacokinetic evidence was noted as lacking in the available nonclinical literature.

---

Product Specifications

These specifications are consistent with the analytical data published in the Certificate of Analysis for CJC-1295 with DAC, which documents purity by RP-HPLC, molecular weight by ESI mass spectrometry, and sequence confirmation by MS/MS.

---

Research Applications

GHRH Receptor Signaling

CJC-1295 w DAC binds and activates the pituitary GHRH receptor, a seven-transmembrane G-protein-coupled receptor that stimulates GH synthesis and secretion from somatotroph cells. Research models examine downstream cAMP signaling, receptor regulation, and the trophic effects of sustained GHRH receptor activation on pituitary function, as reviewed in PubMed’s analysis of GHRH receptor biology.

GH/IGF-1 Axis Studies

The extended half-life of CJC-1295 w DAC enables sustained elevation of circulating GH and downstream IGF-1 in preclinical models. A study published in the American Journal of Physiology demonstrated that once-daily administration of CJC-1295 maintained normal growth parameters and body composition in GHRH knockout mice, with IGF-1 levels showing cumulative elevation over repeated dosing.

Pulsatile vs. Sustained GH Secretion

Unlike short-acting GHRH analogs that mimic natural pulsatile GH release, CJC-1295 w DAC produces a blunted, sustained GH profile due to its albumin-binding modification. This pharmacokinetic difference makes it valuable for research comparing pulsatile versus continuous GH exposure on receptor regulation, metabolic effects, and somatotroph responsiveness, a topic explored in PubMed’s review of GHRH and growth hormone secretagogues in aging.

Pituitary Trophic Effects

Research has demonstrated that CJC-1295 w DAC has important trophic effects on GH-secreting cells of the pituitary, suggesting potential utility in studying GHRH’s role in maintaining somatotroph function. Further mechanistic insights into GHRH receptor signaling pathways are available through PubMed’s recent review of GHRH-R signaling.

---

Quality and Purity

Each batch of CJC 1295 w DAC undergoes rigorous quality control testing to ensure:

• ≥98% purity verified by RP-HPLC

• Correct molecular weight confirmed by ESI mass spectrometry

• Sequence confirmation by MS/MS and Edman degradation

• Peptide content ≥70% by nitrogen analysis

• Endotoxin <0.25 EU/mg by LAL testing

Certificates of Analysis (COA) are available upon request, providing lot-specific documentation for research applications.

---

Frequently Asked Questions

What is CJC 1295 w DAC?

CJC-1295 w DAC is a GHRH analog modified with a Drug Affinity Complex that binds to serum albumin, extending its half-life to approximately 6-8 days. It is used in research to study sustained GH/IGF-1 axis activation.

How does CJC 1295 w DAC differ from CJC-1295 without DAC?

CJC-1295 w DAC has an albumin-binding modification that extends its half-life from roughly 30 minutes to 6-8 days, requiring far less frequent administration in research protocols. The non-DAC version produces pulsatile GH release, while the DAC version produces sustained elevation.

What is the molecular weight of CJC 1295 w DAC?

The molecular weight is approximately 3,401 g/mol, confirmed by mass spectrometry.

What purity level can I expect?

Our CJC-1295 w DAC is provided at ≥98% purity, verified by RP-HPLC.

How should CJC 1295 w DAC be stored?

CJC-1295 w DAC should be stored at -20°C, dry and protected from light. Lyophilised powder should be reconstituted according to standard laboratory protocols.

Is CJC 1295 w DAC FDA-approved?

No. CJC-1295 w DAC is not FDA-approved for any indication and is supplied for research purposes only.

---

Conclusion

CJC-1295 w DAC is a well-characterized long-acting GHRH analog for researchers investigating sustained GH/IGF-1 axis activation, pituitary trophic effects, and the pharmacokinetic differences between pulsatile and continuous GH exposure. Its albumin-binding modification provides a distinct research tool compared to short-acting GHRH analogs.

For researchers requiring a reliable, high-purity CJC-1295 w DAC for their studies, Penguin Peptides Lab provides lab-tested compounds with Certificates of Analysis available upon request.

---

Ready to Advance Your Research?

Order premium CJC-1295 w DAC for your research today. Contact our team for COA requests or technical inquiries.

Call to Action: Shop CJC 1295 w DAC Now

Call to Action: Contact Research Team